Versor Investments LP decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 72.4% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,455 shares of the company's stock after selling 40,600 shares during the quarter. Versor Investments LP's holdings in Hims & Hers Health were worth $457,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Nuveen LLC bought a new position in Hims & Hers Health in the 1st quarter worth approximately $58,403,000. Yong Rong HK Asset Management Ltd boosted its stake in Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after purchasing an additional 700,100 shares during the period. CloudAlpha Capital Management Limited Hong Kong purchased a new stake in Hims & Hers Health during the 1st quarter valued at approximately $20,580,000. Finally, Two Sigma Investments LP raised its position in shares of Hims & Hers Health by 37.9% during the fourth quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock valued at $47,571,000 after buying an additional 540,274 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.
Wall Street Analyst Weigh In
HIMS has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their target price for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. UBS Group set a $30.00 target price on Hims & Hers Health in a research report on Monday, June 23rd. Finally, Morgan Stanley restated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $38.92.
View Our Latest Stock Report on HIMS
Hims & Hers Health Trading Up 1.3%
Shares of NYSE:HIMS traded up $0.57 during trading on Friday, hitting $44.53. The company had a trading volume of 27,930,748 shares, compared to its average volume of 34,221,508. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of 55.66, a price-to-earnings-growth ratio of 3.01 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company has a fifty day simple moving average of $51.71 and a two-hundred day simple moving average of $45.81. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Insider Activity
In related news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares of the company's stock, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,572 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $51.64, for a total transaction of $132,818.08. Following the completion of the sale, the insider directly owned 153,021 shares in the company, valued at $7,902,004.44. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,396,090 shares of company stock worth $71,927,627 over the last 90 days. Insiders own 13.71% of the company's stock.
About Hims & Hers Health
(
Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading

Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.